Filing Flows › Integra Lifesciences Holdings (IART) › Stock forecast & fair value
Integra Lifesciences Holdings (IART) stock forecast and fair value
Integra Lifesciences Holdings (IART) trades at $13.42. 9 analysts' median price target is $14.00 (+4%), from $13.00 to $23.00. Across 24 valuation methods the middle fair value is $6.99 (-48%); the DCF says $0.64.
Fair value by method
| Method | Low | Point | High | vs price |
|---|---|---|---|---|
| Regime-switching Monte Carlo 10th–90th | −$37.66 | −$0.50 | $32.05 | -104% |
| DCF — Monte Carlo 10th–90th percentile | −$28.73 | $0.64 | $23.86 | -95% |
| P/E vs peers | $4.15 | $5.23 | $8.03 | -61% |
| P/E vs peers, weighted | $4.39 | $5.72 | $9.22 | -57% |
| P/E vs peers, matched | $4.49 | $4.78 | $5.99 | -64% |
| EV/Sales vs peers | $44.83 | $64.92 | $115.96 | +384% |
| EV/Sales vs peers, weighted | $50.85 | $80.11 | $128.91 | +497% |
| EV/Sales vs peers, matched | $46.65 | $61.08 | $68.95 | +355% |
| EV/Sales vs peers, growth & margin adjusted | $38.34 | $55.13 | $78.43 | +311% |
| Residual income | $8.72 | $9.03 | $9.35 | -33% |
Integra Lifesciences Holdings' latest quarter
Integra Lifesciences Holdings, Q3 2026: revenue $411M (+2% year over year), operating margin 4.6%, net earnings $14.9M, operating cash flow $96.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for IART stock?
The median of 9 analysts' 12-month targets is $14.00, +4% from $13.42; the range is $13.00 to $23.00. The average rating is hold.
What is Integra Lifesciences Holdings' fair value?
The fair-value methods on Filing Flows (DCF, Monte Carlo, peer multiples and others) put it between −$0.50 and $80.11, with a middle value of $6.99 against a price of $13.42. Each method's assumptions are on the page.
Does Integra Lifesciences Holdings usually beat earnings estimates?
It beat the consensus EPS estimate in 100% of the quarters on record.
Is IART stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.